Johnson & Johnson: New Spectrem Study Findings Reveal Tremfya Effectively Clears Overlooked and Undertreated Plaque Psoriasis
October 26, 2024
October 26, 2024
NEW BRUNSWICK, New Jersey, Oct. 26 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
First-of-its-kind Phase 3b study shows TREMFYA achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement
Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living wi . . .
* * *
First-of-its-kind Phase 3b study shows TREMFYA achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement
Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living wi . . .